FDA’s Peter Stein On Hitting The ‘Persuasive Evidence’ Bar For Rare Disease Drug Repurposing

 
• By Sarah Karlin-Smith
  
old bicycle used as planter
The regulatory pathway can be simpler for repurposed drugs, the FDA’s Peter Stein said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Pink Sheet